These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21584899)

  • 41. Identification of novel target genes by an epigenetic reactivation screen of renal cancer.
    Ibanez de Caceres I; Dulaimi E; Hoffman AM; Al-Saleem T; Uzzo RG; Cairns P
    Cancer Res; 2006 May; 66(10):5021-8. PubMed ID: 16707423
    [TBL] [Abstract][Full Text] [Related]  

  • 42. DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas.
    Malouf GG; Su X; Zhang J; Creighton CJ; Ho TH; Lu Y; Raynal NJ; Karam JA; Tamboli P; Allanick F; Mouawad R; Spano JP; Khayat D; Wood CG; Jelinek J; Tannir NM
    Clin Cancer Res; 2016 Dec; 22(24):6236-6246. PubMed ID: 27256309
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epigenetic silencing of ZBTB28 promotes renal cell carcinogenesis.
    Tong X; Xu L; Rong R; Su X; Xiang T; Peng W; Shi T
    Asia Pac J Clin Oncol; 2022 Apr; 18(2):e79-e86. PubMed ID: 34161675
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Altered transcription and expression of PTEN in breast tumors: is it regulated by hypermethylation?
    Shetty PJ; Pasupuleti N; Chava S; Nasaruddin K; Hasan Q
    Breast Dis; 2011; 33(1):27-33. PubMed ID: 21846942
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients.
    Böck J; Appenzeller S; Haertle L; Schneider T; Gehrig A; Schröder J; Rost S; Wolf B; Bartram CR; Sutter C; Haaf T
    Int J Cancer; 2018 Sep; 143(6):1416-1425. PubMed ID: 29659014
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epigenetic inactivation of the candidate tumor suppressor gene ASC/TMS1 in human renal cell carcinoma and its role as a potential therapeutic target.
    Liu Q; Jin J; Ying J; Cui Y; Sun M; Zhang L; Fan Y; Xu B; Zhang Q
    Oncotarget; 2015 Sep; 6(26):22706-23. PubMed ID: 26093088
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines.
    Kawamoto K; Hirata H; Kikuno N; Tanaka Y; Nakagawa M; Dahiya R
    Int J Cancer; 2008 Aug; 123(3):535-42. PubMed ID: 18404682
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma.
    Ricketts CJ; Morris MR; Gentle D; Brown M; Wake N; Woodward ER; Clarke N; Latif F; Maher ER
    Epigenetics; 2012 Mar; 7(3):278-90. PubMed ID: 22430804
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma.
    Morris MR; Gentle D; Abdulrahman M; Clarke N; Brown M; Kishida T; Yao M; Teh BT; Latif F; Maher ER
    Br J Cancer; 2008 Jan; 98(2):496-501. PubMed ID: 18195710
    [TBL] [Abstract][Full Text] [Related]  

  • 50. DNA methylation of neural EGFL like 1 (NELL1) is associated with advanced disease and the metastatic state of renal cell cancer patients.
    Peters I; Dubrowinskaja N; Hennenlotter J; Antonopoulos WI; Von Klot CAJ; Tezval H; Stenzl A; Kuczyk MA; Serth J
    Oncol Rep; 2018 Dec; 40(6):3861-3868. PubMed ID: 30272321
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.
    Sun G; Zhang X; Liang J; Pan X; Zhu S; Liu Z; Armstrong CM; Chen J; Lin W; Liao B; Lin T; Huang R; Zhang M; Zheng L; Yin X; Nie L; Shen P; Zhao J; Zhang H; Dai J; Shen Y; Li Z; Liu J; Chen J; Liu J; Wang Z; Zhu X; Ni Y; Qin D; Yang L; Chen Y; Wei Q; Li X; Zhou Q; Huang H; Yao J; Chen N; Zeng H
    Clin Cancer Res; 2021 Mar; 27(6):1734-1743. PubMed ID: 33414138
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genome-wide promoter methylome of small renal masses.
    Ibragimova I; Slifker MJ; Maradeo ME; Banumathy G; Dulaimi E; Uzzo RG; Cairns P
    PLoS One; 2013; 8(10):e77309. PubMed ID: 24204800
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CpG hypermethylation of the UCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma.
    Kagara I; Enokida H; Kawakami K; Matsuda R; Toki K; Nishimura H; Chiyomaru T; Tatarano S; Itesako T; Kawamoto K; Nishiyama K; Seki N; Nakagawa M
    J Urol; 2008 Jul; 180(1):343-51. PubMed ID: 18499164
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma.
    Nojima D; Nakajima K; Li LC; Franks J; Ribeiro-Filho L; Ishii N; Dahiya R
    Mol Carcinog; 2001 Sep; 32(1):19-27. PubMed ID: 11568972
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epigenetic alterations of Krüppel-like factor 4 and its tumor suppressor function in renal cell carcinoma.
    Li H; Wang J; Xiao W; Xia D; Lang B; Yu G; Guo X; Guan W; Wang Z; Hu Z; Liu J; Ye Z; Xu H
    Carcinogenesis; 2013 Oct; 34(10):2262-70. PubMed ID: 23722653
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Promoter CpG island methylation in ion transport mechanisms and associated dietary intakes jointly influence the risk of clear-cell renal cell cancer.
    Deckers IA; van Engeland M; van den Brandt PA; Van Neste L; Soetekouw PM; Aarts MJ; Baldewijns MM; Keszei AP; Schouten LJ
    Int J Epidemiol; 2017 Apr; 46(2):622-631. PubMed ID: 27789672
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma.
    Tokinaga K; Okuda H; Nomura A; Ashida S; Furihata M; Shuin T
    Oncol Rep; 2004 Oct; 12(4):805-10. PubMed ID: 15375503
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma.
    Eggers H; Steffens S; Grosshennig A; Becker JU; Hennenlotter J; Stenzl A; Merseburger AS; Kuczyk MA; Serth J
    Int J Oncol; 2012 May; 40(5):1650-8. PubMed ID: 22327210
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway.
    Zhou XP; Waite KA; Pilarski R; Hampel H; Fernandez MJ; Bos C; Dasouki M; Feldman GL; Greenberg LA; Ivanovich J; Matloff E; Patterson A; Pierpont ME; Russo D; Nassif NT; Eng C
    Am J Hum Genet; 2003 Aug; 73(2):404-11. PubMed ID: 12844284
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inactivation of BHD in sporadic renal tumors.
    Khoo SK; Kahnoski K; Sugimura J; Petillo D; Chen J; Shockley K; Ludlow J; Knapp R; Giraud S; Richard S; Nordenskjöld M; Teh BT
    Cancer Res; 2003 Aug; 63(15):4583-7. PubMed ID: 12907635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.